title: Enhanced thrombin generation in women with a history of oral contraception-related venous thrombosis.
abstract: BACKGROUND
  In women who suffer venous thrombosis (VT) during oral contraceptive (OC) use, a transient risk factor (OC) is removed during the acute event, while most co-existing forms of thrombophilia persist and presumably continue to maintain hypercoagulability. The aim of this study was to establish if hypercoagulability persists long after OC-related VT and if it could be attributed to thrombophilia.
  
  
  METHODS
  60 women (age 33.0 ± 8.5 years) were investigated 5 - 64 (median 33) months after OC-related VT (patients) and compared to 63 apparently healthy women (controls). All women were tested for thrombophilia, activated partial thromboplastin time (APTT), fibrinogen, D-dimer, P-selectin and C-reactive protein. Thrombin generation was measured by Technothrombin® TGA assay. Overall haemostasis potential (OHP) assay with overall coagulation potential (OCP) and overall fibrinolytic potential (OFP) as supplementary parameters were measured by repeated fibrin formation and degradation registration.
  
  
  RESULTS
  In patients increased endogenous thrombin potential (4,205 ± 440 nM x min vs 4,015 ± 421 nM x min, p=0.017), increased OCP (22.6 ± 4.6 Abs-sum vs 20.8 ± 4.1 Abs-sum, p=0.025), shorter APTT (30.9 ± 3.8s vs 33.4 ± 3.6s, p<0.001) and lower antithrombin activity (99, 93-105% vs 104, 100-109%, p<0.05) were observed. Thrombophilia was observed in 22/60 (36%) patients and in 5/63 (7.9%, p<0.001) controls. The only significant difference between thrombophilic and non-thrombophilic patients was higher soluble P-selectin in the former subgroup (22, 20-33 μg/L vs 17, 12-22 μg/L, p=0.012).
  
  
  CONCLUSIONS
  In women with a history of OC-related VT persistent hypercoagulability was observed, which, however was not augmented by the presence of thrombophilia.
authors.affiliation: Department of Vascular Diseases, University Medical Centre, Ljubljana, Slovenia.
authors.forename: Saša
authors.initials: S
authors.lastname: Anžej Doma
authors.forename: Maja
authors.initials: M
authors.lastname: Vučnik
authors.forename: Mojca
authors.initials: M
authors.lastname: Božič Mijovski
authors.forename: Polona
authors.initials: P
authors.lastname: Peternel
authors.forename: Mojca
authors.initials: M
authors.lastname: Stegnar
mesh_terms: D000328:Adult; D001780:Blood Coagulation Tests; D003276:Contraceptives, Oral / Q000009:adverse effects*; D005260:Female; D006801:Humans; D013917:Thrombin / Q000378:metabolism*; D019851:Thrombophilia / Q000097:blood / Q000150:complications*; D020246:Venous Thrombosis / Q000097:blood / Q000139:chemically induced* / Q000150:complications* / Q000378:metabolism
chemical_list: D003276:Contraceptives, Oral; D013917:Thrombin
keywords: APTT; ETP; OC; OCP; OFP; OHP; VT; activated partial thromboplastin time; endogenous thrombin potential; oral contraception; oral contraceptive(s); overall coagulation potential; overall fibrinolytic potential; overall haemostasis potential; thrombophilia; venous thrombosis